An experienced life sciences industry executive, Andi leads VMS in its mission to make real-world connections with patients to achieve better outcomes.

Serving as President and CEO of VMS BioMarketing, Andi has 28 years of commercialization and general management experience in the biopharmaceutical industry across numerous senior leadership roles and therapeutic areas in both both public and private companies. She brings extensive knowledge about the areas of endocrinology, osteoporosis, and women’s health as well as unique insights about patient behavior and adherence. She has demonstrated proven results in the development and execution of biopharmaceutical commercialization strategies that resulted in consistent revenue and pro?t growth.

Andi spent 18 years at Eli Lilly and Company in various positions of increasing responsibility. She held finance, business development, corporate affairs, brand management and business unit leadership roles. She was the marketing leader for the launch of Humalog® Mix75/25™ in the Diabetes Business Unit. She led sales and marketing for Humatrope®, as the Business Unit Leader for Lilly’s Growth Hormone Franchise that included launching two new indications and a new delivery device. She was the Osteoporosis Business Unit Leader with responsibility for the development and launch of Forteo® and worked directly with the FDA on the development and execution of Lilly’s first risk evaluation and mitigation strategy (REMS) program. She subsequently took over responsibility for Evista® and became the Business Unit Leader of Lilly’s Women’s Health Business. In these roles, she developed and successfully implemented customer-focused sales models, repositioned late-stage products that resulted in increased market share growth, and created innovative patient, caregiver, and provider education and engagement programs.

Earlier in her career, Andi worked as a management consultant for Putnam Associates, where she led consulting teams and advised brands in the biotech, pharmaceutical and managed healthcare ?elds on product launches and access strategies.

After joining VMS BioMarketing in 2008 to lead the company’s Strategic Marketing and Brand Development Business Units, Andi was named President and CEO in 2011. Within her first year, she spun-off commoditized business units and focused the company solely on impacting patient adherence and outcomes. During her 10 years as CEO, she has established VMS as the leading provider and growth leader of Clinical Nurse Educator patient support solutions. Andi provides strategic consulting to VMS biopharma clients on pre- and post-commercialization strategies across a broad range of therapeutic areas including immunology, oncology, endocrinology, neuroscience and rare diseases. She is a regular speaker and panel member on patient adherence, patient services and women’s leadership topics at biopharma industry conferences.

Andrea currently serves on the board of directors of life sciences companies Rockwell Medical and atai pharma, and is an Advisor for Agent Capital, a healthcare venture capital firm. She previously served on Assertio Therapeutics, Zyla Life Sciences, Egalet Corporation and AppianRx. Additionally, she currently serves on the board of the Indiana Alzheimer’s Association and the Mitch Daniels Leadership Foundation. In previous years, she served on the board of the Indiana Salvation Army, Summer Stock, the Lung Force Women’s Cabinet, and she received a gubernatorial appointment to the Indiana Commission for Women. She earned her BA in economics from DePauw University where she was an Honors Management Fellow.